U.S. CDC advisory committee recommends lowering age for receiving RSV vaccinatons

Vaccine advisory panel recommends expanded RSV use, and two new vaccines The Advisory Committee on Immunization Practices voted Wednesday to recommend lowering the age at which adults can get a vaccine against respiratory syncytial virus. Helen Branswell STAT

A committee of independent vaccine experts voted Wednesday to recommend lowering the age at which adults can get a vaccine against respiratory syncytial virus, potentially opening up access to these vaccines for adults in their 50s who are at high risk of severe illness from RSV. 

The Advisory Committee on Immunization Practices voted to recommend that any RSV vaccine for adults that is licensed by the Food and Drug Administration for high-risk adults aged 50 to 59 be recommended for use in that age group. If the recommendation is accepted by the Centers for Disease Control and Prevention — which the ACIP advises — insurance companies will have to cover the cost of the vaccine for eligible individuals.

...